Estrogenic regulation of tissue factor and tissue factor pathway inhibitor in platelets.
Oral estrogen treatment increases thrombotic risk. Tissue factor (TF), tissue factor pathway inhibitor (TFPI), and platelet interaction with leukocytes are important determinants of thrombogenesis. Therefore, the present study was designed to define and compare platelet TF and TFPI mRNA and adhesion protein expression in platelets derived from animals treated with different types of oral estrogens. Ovariectomized pigs were treated with 17beta-estradiol (2 mg/day), conjugated equine estrogen (CEE; 0.625 mg/day), or raloxifene (60 mg/day) for 4 wk. Compared with intact animals, ovariectomy and treatment differentially affected populations of leukocytes: neutrophils decreased whereas lymphocytes increased significantly 4 wk after ovariectomy and with 17beta-estradiol and CEE treatments; eosinophils increased only with 17beta-estradiol treatment. Content of TF protein increased in platelets from 17beta-estradiol- and raloxifene-treated pigs, whereas TF mRNA was detected only in platelets from 17beta-estradiol- and CEE treated pigs. TFPI mRNA increased in platelets after ovariectomy and estrogen treatment. Only a trace of TFPI protein was detected, but a higher-molecular-mass protein was observed in all treatment groups. Expression of CD40 and CD40 ligand increased with ovariectomy and decreased with 17beta-estradiol and CEE treatments more than with raloxifene. The ratio of activated to basal P-selectin expression decreased with ovariectomy and increased with raloxifene treatments. These results suggest that estrogenic formulations may affect individual thrombotic risk by different mechanisms that regulate TF and platelet-leukocytic interactions. These studies provide the rationale for evaluation of interactions among platelets and TF and TFPI expression on thrombin generation during estrogen treatment in humans.
Jayachandran
Muthuvel
M
Dept. of Surgery, Mayo Clinic College of Medicine, 200 First St. SW, Rochester, MN 55905, USA.
Sanzo
Antonio
A
Owen
Whyte G
WG
Miller
Virginia M
VM
D000199:Actins / Q000096:biosynthesis; D000818:Animals; D017304:Annexin A5 / Q000378:metabolism; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D019013:CD40 Antigens / Q000378:metabolism; D004958:Estradiol / Q000494:pharmacology; D004965:Estrogen Antagonists / Q000494:pharmacology; D004967:Estrogens / Q000494:pharmacology*; D004966:Estrogens, Conjugated (USP) / Q000494:pharmacology; D005260:Female; D005434:Flow Cytometry; D015151:Immunoblotting; D066298:In Vitro Techniques; D008074:Lipoproteins / Q000096:biosynthesis / Q000097:blood*; D010052:Ovariectomy; D019007:P-Selectin / Q000378:metabolism; D012313:RNA / Q000097:blood / Q000302:isolation & purification; D012333:RNA, Messenger / Q000096:biosynthesis; D020849:Raloxifene Hydrochloride / Q000494:pharmacology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013552:Swine; D013925:Thromboplastin / Q000096:biosynthesis / Q000378:metabolism*
D000199:Actins; D017304:Annexin A5; D019013:CD40 Antigens; D004965:Estrogen Antagonists; D004967:Estrogens; D004966:Estrogens, Conjugated (USP); D008074:Lipoproteins; D019007:P-Selectin; D012333:RNA, Messenger; C051928:lipoprotein-associated coagulation inhibitor; D020849:Raloxifene Hydrochloride; D004958:Estradiol; D012313:RNA; D013925:Thromboplastin